LINCS MCF 10A Common Project: Rolling-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Dataset 1 of 15: End-point cell counts and normalized growth rate inhibition values for all technical replicates of biological replicate 1. - Dataset (ID:20309)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Time Point (hr) | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value | Assay Plate | Assay Well |
|---|---|---|---|---|---|---|---|---|---|---|
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 47.83 | 770.25 | 902 | 6223 | 0.1449 | 0.0538 | MN20160304_L02 | N03 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 50.05 | 770.25 | 947 | 6629 | 0.1429 | 0.0688 | MN20160304_L02 | F05 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 50.05 | 770.25 | 889 | 6629 | 0.1341 | 0.0473 | MN20160304_L02 | N03 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 52.27 | 770.25 | 924 | 7058 | 0.1309 | 0.0586 | MN20160304_L02 | F05 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 52.27 | 770.25 | 895 | 7058 | 0.1268 | 0.0481 | MN20160304_L02 | N03 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 54.49 | 770.25 | 920 | 7555 | 0.1218 | 0.0554 | MN20160304_L02 | F05 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 54.49 | 770.25 | 840 | 7555 | 0.1112 | 0.0267 | MN20160304_L02 | N03 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 56.71 | 770.25 | 871 | 8001 | 0.1089 | 0.0371 | MN20160304_L02 | F05 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 56.71 | 770.25 | 845 | 8001 | 0.1056 | 0.0278 | MN20160304_L02 | N03 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 58.94 | 770.25 | 864 | 8444 | 0.1023 | 0.0338 | MN20160304_L02 | F05 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 58.94 | 770.25 | 808 | 8444 | 0.0957 | 0.0139 | MN20160304_L02 | N03 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 61.16 | 770.25 | 835 | 8892 | 0.0939 | 0.0231 | MN20160304_L02 | F05 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 61.16 | 770.25 | 773 | 8892 | 0.0869 | 0.0010 | MN20160304_L02 | N03 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 63.39 | 770.25 | 803 | 9326 | 0.0861 | 0.0116 | MN20160304_L02 | F05 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 63.39 | 770.25 | 790 | 9326 | 0.0847 | 0.0071 | MN20160304_L02 | N03 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 65.61 | 770.25 | 800 | 9736 | 0.0822 | 0.0104 | MN20160304_L02 | F05 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 65.61 | 770.25 | 762 | 9736 | 0.0783 | -0.0029 | MN20160304_L02 | N03 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 67.83 | 770.25 | 771 | 10078 | 0.0765 | 0.0003 | MN20160304_L02 | F05 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 67.83 | 770.25 | 739 | 10078 | 0.0733 | -0.0111 | MN20160304_L02 | N03 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 70.05 | 770.25 | 736 | 10413 | 0.0707 | -0.0120 | MN20160304_L02 | F05 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 70.05 | 770.25 | 748 | 10413 | 0.0718 | -0.0078 | MN20160304_L02 | N03 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 72.27 | 770.25 | 705 | 10730 | 0.0657 | -0.0230 | MN20160304_L02 | F05 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 72.27 | 770.25 | 711 | 10730 | 0.0663 | -0.0208 | MN20160304_L02 | N03 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 74.50 | 770.25 | 689 | 10991 | 0.0627 | -0.0286 | MN20160304_L02 | F05 |
| MCF 10A-H2B-mCherry | Dasatinib | 10 | 74.50 | 770.25 | 726 | 10991 | 0.0661 | -0.0153 | MN20160304_L02 | N03 |